Table 1 | Table 2 | Table 3

The all_drugs dataset | Buprenorphine Details | Alcohol | The asi dataset | The demographics dataset | The detox dataset | The everybody dataset | The fagerstrom dataset | The first_survey dataset | The pain dataset | The psychiatric dataset | The randomization dataset | The rbs dataset | The rbs_iv dataset | The screening_date dataset | The sex dataset | The tlfb dataset | The treatment dataset | The uds dataset

Introduction | Calculate Induction Delay | Data Setup | Mark Study Days with Administered Treatment Drugs | Measure Difference from Randomization Day to Day of First Dose | Partition Visit Weeks and Impute Missing Visits | "Backbone" Timeline of Clinical Protocol | CTN-0027 and CTN-0051 Protocols | CTN-0030 Protocol | Combined "Backbone" | Mark Missing Visits | Add First Randomization Day | Add on the Visit Days | Impute the Missing Visits | Clean up the Results | Summarize Weekly Substance Use Results | Participant's Assigned Treatment | Counting Days Since Randomization | Symbolically Summarize Participant UDS by Study Week | Symbolically Summarize Non-Randomized Participants UDS by Study Week | Final Product | Wrapping Up

Introduction | Abstinence from Substance Use Endpoints | CTN-0094 Abstinence | @fiellin_counseling_2006 | @kosten_buprenorphine_1993 | @krupitsky_injectable_2011 (A) and (B) | Krupitsky et al., 2011 (A) | Krupitsky et al., 2011 (B) | @ling_buprenorphine_1998 | @lofwall_weekly_2018 | @mokri_medical_2016 | @schottenfeld_methadone_2005 | @schottenfeld_maintenance_2008 (A) and (B) | Schottenfeld, Chawarski, & Mazlan, 2008 (A) | Schottenfeld et al., 2008 (B) | @shufman_efficacy_1994 | @weiss_adjunctive_2011 [CTN-0030] | Computing Environment | References

Introduction | Substance Use Reduction Endpoints | @comer_injectable_2006 | @eissenberg_dose-related_1997 | @fiellin_counseling_2006 | @fudala_office-based_2003 | @haight_efficacy_2019 | @jaffe_methadyl_1972 | @johnson_controlled_1992 | @kosten_buprenorphine_1993 | @ling_buprenorphine_1998 (A) and (C) | Ling et al., 1998 (A) | Ling et al., 1998 (C) | @ling_buprenorphine_2010 | @ling_methadyl_1976 | Original | A Variant | @lofwall_weekly_2018 | @mattick_buprenorphine_2003 (A) and (B) | Mattick et al., 2003 (A) | Mattick et al., 2003 (B) | @pani_buprenorphine_2000 (A) and (B) | Pani et al., 2000 (A) | Pani et al., 2000 (B) | @petitjean_double-blind_2001 | @preston_methadone_2000 | @schottenfeld_methadone_2005 | @schwartz_randomized_2006 | @shufman_efficacy_1994 | @soyka_retention_2008 | @strain_dose-response_1993 | @strain_comparison_1994 | @strain_buprenorphine_1996 | @strain_moderate-_1999 | @strang_supervised_2010 | @strang_extended-release_2019 | @tanum_effectiveness_2017 | @wolstein_randomized_2009 | @woody_extended_2008 | @zaks_levomethadyl_1972 | Computing Environment | References

Introduction | "Relapse to Substance Use" Endpoints | CTN-0094 Endpoints | CTN-0094 Relapse | CTN-0094 Dropout | @johnson_controlled_1992 | @krupitsky_naltrexone_2004 and @krupitsky_naltrexone_2006 | @lee_extended-release_2016 | @lee_comparative_2018 [CTN-0051] | @schottenfeld_maintenance_2008 | Computing Environment | References

Fix dea_brands | Fix DEA category and class | The DEA street name file has:

Mark names that will be diffcult to parse | Difficult synonyms | Easy synonyms | bind the 'easy' and 'difficult' synonym datasets to create the final dataset

DEA | Web Scrape | Fact Sheets | Drug Brands | PDFs | Slang | Controlled Substances | DEA Summary | No Slang | IQVIA | drug_stop_words.rda

Data: drug_df | parse() | lookup_* | lookup() | compress_lookup() | lookup_syn()

Scrape No Slang Data | Finding Drug Names

Write a function to get the name, category and path of a drug